OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Voorhees on the Clinical Implications of Cilta-Cel in Relapsed/Refractory Myeloma

July 9th 2025

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC

July 8th 2025

Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.

Dr Haas on the Safety Profile of Adjuvant Pembrolizumab in Clear Cell RCC

July 8th 2025

Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Dr Mehnert on the Efficacy of Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab in Unresectable Melanoma

July 8th 2025

Janice M. Mehnert, MD, discusses the efficacy and safety profile of sarilumab plus ipilimumab, nivolumab, and relatimab in unresectable melanoma.

Dr Lotan on Guideline-Supported Treatment Decision-Making for NMIBC

July 7th 2025

Yair Lotan, MD, discusses guideline-supported treatment avenues for patients with BCG-unresponsive NMIBC.

Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC

July 7th 2025

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

July 7th 2025

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

Dr Olawaiye on Phase 2 Data With Relacorilant and Nab-Paclitaxel in Ovarian Cancer

July 7th 2025

Alexander B. Olawaiye, MD, discusses data with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer that led to the phase 3 ROSELLA trial.

Dr Finn on Adding Tiragolumab to Atezolizumab and Bevacizumab in Locally Advanced or Metastatic HCC

July 5th 2025

Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Dr García-Carbonero on Outcomes With Fruquintinib in R/R mCRC by Metastatic Sites

July 5th 2025

Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.

Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC

July 4th 2025

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

July 4th 2025

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Dr O’Reilly on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer

July 3rd 2025

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC

July 3rd 2025

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC

July 3rd 2025

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL Therapy in Advanced Melanoma

July 3rd 2025

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Dr Cardoso on the Effect of Elinzanetant on Vasomotor Symptoms in HR+ Breast Cancer

July 3rd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of Adjuvant Chemo in NSCLC

July 2nd 2025

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

Dr Daver on Initial Efficacy and Safety Data With Bexmarilimab Plus Azacitidine in Higher-Risk MDS

July 2nd 2025

Naval G. Daver, MD, discusses early efficacy and safety data for bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndrome.

Dr Tarhini on Neoadjuvant Pembrolizumab Plus Vidutolimod in Resectable Melanoma

July 2nd 2025

Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.